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Incidence, risk factors, and prognosis of gastrointestinal hemor- Despite the considerable progress in medical technol-
rhage complicating acute renal failure. ogy and improvements in clinical management of the
Background. Few prospective data are currently available past few years, acute renal failure (ARF) is still associ-on acute gastrointestinal hemorrhage (AGIH) as a complica-
ated with high in-hospital mortality [1].tion of acute renal failure (ARF). The aim of the present study
The clinical course of ARF patients who eventuallywas to define incidence, sources, risk factors, and outcome of
AGIH in patients with ARF. die is characterized by stormy nonrenal complications,
Methods. We performed a prospective study on an inception such as central nervous system alterations, sepsis, cardiac
cohort of 514 patients admitted for ARF to a nephrology inter-
arrhythmias, and bleeding [2].mediate care unit. Data on clinical risk factors for bleeding,
Studies over the last 30 years suggest that acute gastro-frequency of occurrence of AGIH, length of hospital stay, and
in-hospital mortality were collected. Independent predictors intestinal hemorrhage (AGIH), especially in the upper
of AGIH were identified. The relative odds of death and the rel- gastrointestinal tract, is the most frequent bleeding com-
ative increase in length of hospital stay associated with AGIH plication of ARF, even though the reported incidencewere calculated after adjusting for baseline comorbidities.
ranges widely, from 8 to 36.8% [2–15]. None of the stud-Results. Sixty-nine patients out of 514 [13.4% (95% CI, 10.6
to 16.7)] had AGIH as a complication of ARF; 59 were upper ies published so far have specifically investigated AGIH
AGIH. Forty patients had clinically important bleeding. Ero- in patients with ARF. Most of them are retrospective
sions and/or ulcers accounted for 71% of cases of upper AGIH. collections of ARF complications [2–7, 9–15] and often
Independent baseline predictors of AGIH were represented
include only specific subgroups of ARF patients [2, 6, 12].by severity of illness [odds ratio 1.45 (95% CI, 1.05 to 2.01)
Also, a clear definition of AGIH in terms of clinicalfor every 10 point increase in APACHE II score], low platelet
count [,50,000 mm3; 3.71 (1.70 to 8.11)], noncirrhotic chronic severity is lacking [2–15], and to our knowledge, no study
hepatic disease [2.22 (1.09 to 4.55)], liver cirrhosis [3.38 (1.50 has documented the source of AGIH by endoscopic ex-
to 7.60)], de novo ARF [2.77 (1.30 to 5.90)], and severe ARF
amination. Finally, most studies were done before the[2.07 (1.10 to 3.88)]. In-hospital mortality was 63.8% in patients
era of extensive pharmacological prophylaxis of upperwith AGIH and 34.2% in the other patients; after adjusting for
baseline confounders, AGIH remained significantly associated gastrointestinal tract stress-related lesions (the so-called
with an increase in both mortality [2.57 (1.30 to 5.09), P 5 stress ulcer syndrome) in critically ill patients.
0.006] and length of hospital stay [37% (1 to 87%), P 5 0.047]. No study has provided evidence yet concerning riskConclusions. AGIH and clinically important bleeding are
indicators for AGIH in ARF. Uremia per se is thoughtfrequent complications of ARF. In this clinical condition,
to cause bleeding diathesis by impairing platelet aggrega-AGIH is more often due to upper gastrointestinal bleeding
and is associated with a significantly increased risk of death tion and platelet–vessel wall interaction [16], but ARF
and length of hospital stay. Both renal and extrarenal risk patients can have many other comorbidities that further
factors are related to the occurrence of AGIH.
increase hemorrhagic risk, for example, disseminated in-
travascular coagulation, sepsis, and hepatic failure. Fi-
nally, few data on the outcomes of patients with ARF
complicated by AGIH are currently available.
We thus studied an inception cohort of patients admit-Key words: critical care, bleeding complication, intensive care, hemo-
stasis, histamine2-receptor antagonists, kidney failure. ted for ARF to an intermediate care nephrology unit.
Our aims were as follows: (1) to investigate the incidence,
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between the occurrence of AGIH and both increased with a histamine-2 (H2)-receptor antagonist (ranitidine)
was maintained in all patients during the entire hospi-in-hospital mortality and length of hospital stay in ARF
patients. tal stay.
Data collection
In January 1994, a prospective database was estab-METHODS
lished at our department in order to study prognosticStudy population
indicators of morbidity and mortality in ARF [17, 19].
All patients consecutively admitted for ARF during a Prognostic indexes for ARF were chosen by literature
six-year period (January 1, 1994, to December 31, 1999) review and the authors’ judgment on the basis of clinico-
to the renal intermediate care unit of the Internal Medi- biological plausibility and epidemiologic importance.
cine and Nephrology Department, in a 1500 bed acute- Characteristics of potential prognostic significance, such
care, university-based teaching hospital were included as demographic data, premorbid conditions, primary and
in the study. The intermediate nephrology care unit is a concomitant diagnoses, nutritional status, clinical param-
closed six-bed specialty unit for ARF patients, with a eters, and laboratory data, all referred to the time of
bed-to-nurse ratio of 3:1. It is staffed by nephrologists admission, were recorded on preprinted forms by experi-
with advanced experience in critical care nephrology. enced medical personnel. Definitions of premorbid con-
All patients with ARF in the hospital are usually referred ditions and acute comorbidities were derived from the
to the unit if they are not on mechanical ventilation at literature and are reported in detail in the Appendix
the time of referral. [20–30]. Nutritional status at admission was evaluated by
Acute renal failure was defined as an abrupt decline the Subjective Global Assessment of Nutritional Status
in renal function with a recent rise (24 to 48 hours) in method [31], as previously described [17]. For each pa-
plasma creatinine values of more than 50% above base- tient, the Acute Physiology and Chronic Health Evalua-
line status in the absence of volume responsive prerenal tion score in version II was calculated at 24 hours from
status. In the case of pre-existing renal disease or known admission [19, 32]. Following admission, data concerning
renal insufficiency not previously dialyzed and not con- treatments, procedures, and complications during the
sidered end-stage renal disease, patients were required patient’s stay were collected. Renal replacement therapy
to demonstrate an increase in serum creatinine levels of required until death, hospital discharge, or treatment
at least 1 mg/dL from their baseline status (acute-on- discontinuation was recorded as hemodialysis or contin-
chronic renal failure) [17]. uous venovenous hemofiltration; in the case of continu-
The study was noninterventional. Thus, primary physi- ous venovenous hemofiltration preceded or followed by
cians determined the management of each patient, in hemodialysis, patients were classified as continuous ven-
particular renal replacement therapies and AGIH diag- ovenous hemofiltration. No index of the intensity of dial-
nostic assessment and therapy. As the National Health ysis delivered was routinely measured during the study.
System covers medical care in Italy, there was no access Other data collected were represented by the need for
restriction to treatment. The standard hemodialysis sched- artificial nutrition and the use of medications relevant
ule was at least four hours every other day; conventional to hemostasis at time of admission or at any time after
bicarbonate hemodialysis was performed through central admission to the nephrology unit (aspirin, oral anticoag-
venous access by double or triple lumen catheters (inter- ulants on full therapeutic dose, nonfractionated heparin,
nal jugular or subclavian veins) [18], with an ultrafiltra- low molecular weight heparin for venous thrombosis
tion-controlled delivery system, polymethylmetacrylate prophylaxis).
or polysulfone hollow fiber filters, and heparin as antico- We prospectively identified cases that developed acute
agulant. The heparin-free hemodialysis method with gastrointestinal bleeding (AGIH) after admission to the
ethylvinylalcohol, polysulfone, or polymethylmetacry- nephrology unit. A distinction was made between defi-
late filters was used for patients considered at hemor- nite complications in the course of ARF and comorbidi-
rhagic risk at the start of renal replacement therapy. Con- ties, that is, conditions present before or at the time of
tinuous renal replacement therapy was performed as admission to the nephrology unit (Appendix). Gastro-
continuous venovenous hemofiltration by using the same intestinal bleeding was classified as an acute complication
filters as for hemodialysis, usually with prostacyclin as if bleeding occurred at least 24 hours after admission to
circuit antiaggregant at the dose of 4 ng/kg/min infused the nephrology unit; it was classified as acute comorbidity
before the filter. The indications for continuous renal when the onset was before or up to 24 hours after admis-
replacement therapies were represented by ARF with sion. The definition of gastrointestinal bleeding as a co-
hypotension and/or severe hemodynamic instability morbidity also encompassed cases in which bleeding pre-
and/or severe fluid overload and/or hypercatabolism. ceded admission but continued or recurred during the
hospital stay. AGIH and clinically important bleedingPharmacological prophylaxis of stress ulcer syndrome
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Table 1. Definitions and classification of gastrointestinal bleeding chronic comorbidities (Appendix), platelet count, pro-
thrombin activity, serum blood urea nitrogen, and creati-Acute gastrointestinal hemorrhage (AGIH)
Direct evidence of bleeding (hematemesis, red blood that does not nine levels.
clear with 0.5 L of lavage, or “coffee ground” material in nasogastric All of the regression analyses were limited to the 512aspirate, hematochezia) or objective description of indirect evidence
patients with an available APACHE II score. To avoidof upper gastrointestinal tract bleeding (black stool on digital rectum
examination or melena) having to exclude the 26 patients with missing prothrom-
bin activity, we defined a “missing prothrombin activity”Clinically important bleeding
AGIH complicated by one of the following within 24 hours after indicator variable.
the onset of bleeding (in the absence of other causes): Logistic regression was employed for analysis concern-(a) A spontaneous decrease of more than 20 mm Hg in the systolic
ing AGIH predictors and for analysis of the associationblood pressure
(b) An increase of more than 20 beats per minute in the heart rate, between death and AGIH. The linearity of the relation-
or a decrease of more than 10 mm Hg in the systolic blood ship between continuous variables and the logit was as-pressure measured with the patient sitting up
sessed graphically and by testing polynomial transforma-(c) A decrease in the hemoglobin level of more than 2 g per deciliter
(1.2 mmol/L) and transfusion of 2 units of blood within 24 hours tions of the covariates. If indicated, the continuous
(d) Bleeding requiring surgery variables were divided into categories. Each defined cat-
Upper gastrointestinal source of hemorrhage egory was coded as indicator variable (1 if yes and 0 if
(a) Diagnostic procedures (endoscopy, angiography, etc.) demon- otherwise). Every hypothesis test (P value) was verifiedstrating the source of hemorrhage to be above the ligament of
by the likelihood ratio test. The goodness-of-fit was as-Treitz
(b) Clinical criteria, that is, the presence of red blood or “coffee sessed with the Hosmer-Lemeshow C statistic [34].
ground” material by emesis or nasogastric tube or the presence To identify the independent predictors of AGIH, allof black tarry stool
baseline variables and 43 clinically meaningful first-order
Lower gastrointestinal source of hemorrhage
product terms were entered into a multiple regression(a) Diagnostic procedures (for example scintigraphy with technetium
equation. The subgroup of variables that jointly pre-99m-labeled red blood cells, angiography, colonoscopy) demon-
strating the source of hemorrhage to be in the colon dicted AGIH at a significance level of P , 0.05 was
(b) Clinical criteria, that is, the passage of bright red blood per selected by a backward-elimination procedure. Addi-rectum
tionally, the same analysis was repeated to identify pre-
dictors of clinically important bleeding, using clinically
important bleeding as the dependent variable.
To measure the association between mortality andwere defined according to Cook et al (Table 1) [33].
AGIH, the crude odds ratio of death associated withSources of bleeding were diagnosed on the basis of endo-
AGIH was calculated. Subsequently, the odds ratio wasscopic examinations or other gastrointestinal tract diag-
adjusted for all the baseline variables.nostic procedures (angiographies, computed tomogra-
Ordinary least-square regression analysis was used tophy scan, etc.). The number of packed red cell units
explore the relationship between AGIH and the lengthtransfused during hospital stay was recorded. Mortality
of hospital stay among patients who survived. The mean
was defined as death during hospital stay (in-hospital length of hospital stay in patients with and without AGIH
mortality); the length of hospital stay in days was also was compared; because of the skewed distribution of these
recorded. data and of the residuals, length of stay data were log-
The database was periodically checked for missing transformed. Subsequently, the b coefficient for AGIH
data and errors. Two patients had missing data for the and its confidence limits were back transformed by taking
APACHE II score (one of them for Systemic Inflamma- the antilog. Since the difference between the logarithm
tory Response Syndrome as well); 26 patients had miss- of two values is the same as the logarithm of their ratio,
ing prothrombin activity values at admission, and 1 pa- it follows that the antilog of the b coefficient will be the
tient had missing data on length of stay. Missing data estimate of the ratio of the geometric mean for patients
were due to logistic reasons and, therefore, they are with AGIH to the geometric mean for patients without
likely to be random. AGIH (that is, the relative increase in mean days of stay
Approval from the local ethics committee was not associated with AGIH) [35]. The b coefficient was ad-
required for the use of data already collected for clin- justed for all baseline variables.
ical use. All analyses were made using the Stata Statistical Soft-
ware package (release 6.0; StataCorp., College Station,
TX, USA).Statistical analysis
A set of “baseline variables” was defined according
RESULTSto the characteristics recorded at time of admission: age,
gender, APACHE score, type of referral (intensive care The study population consisted of 514 subjects with
ARF. Demographic and clinical characteristics of theunit, medical/surgical, emergency surgery), acute and
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Table 4. Clinical diagnosis of AGIH (69 cases)Table 2. Demographic and clinical data of the ARF patient cohort
(N 5 514)
Clinical diagnosis
Age years 68.3 (14.5)
Blood in nasogastric tube aspirateMale sex 330/514 (64.2%)
(red blood or “coffee ground” material) 24/69 (34.8%)APACHE scorea 23.3 (8.1)
Hematemesis 11/69 (15.9%)Serum creatininea mg/dL 5.2 (1.7–14.8)
Melena 24/69 (34.8%)BUNa mg/dL 82 (29–204)
Hematochezia 10/69 (14.5%)Surgical ARF 152/514 (29.6%)
Acute tubular necrosis 361/514 (70.2%)
Renal replacement therapies
(bicarbonate hemodialysis or
continuous venovenous hemo-
Table 5. Endoscopic diagnosis of AGIH (48 endoscopic proceduresfiltration) 320/514 (62.3%)
in 69 AGIH cases)Continuous venovenous hemo-
filtration 50/320 (15.6%) Upper gastrointestinal tract Lower gastrointestinal tract
Heparin during hemodialysis
Diagnosis N Diagnosis N(at least in one session) 154/260 (59.2%)
Nutritional support Esophagitis 1 Ischemic colitis 2
Per os 200/514 (38.9%) Esophageal varices 5 Infective colitis 2
Total enteral nutrition 60/514 (11.7%) Gastric erosions
Total parenteral nutrition 21/514 (4.1%) and/or ulcers 20 Aspecific colitis 1
Enteral1parenteral nutrition 233/514 (45.3%) Gastric neoplasia 3 Ulcerative colitis 1
Post-chemotherapyContinuous variables are presented as mean (SD) or median (95%
Duodenal ulcers 6 colitis 1central range).
Postoperative biliarya At the time of admission
tract bleeding 1
No lesion founda 2 No lesions founda 3
a Negative endoscopic evaluation but clinical diagnosis of AGIH
Table 3. Acute and chronic comorbidities of the ARF patient cohort
Patients
(N5514)
bleeding, whereas 4 out of 10 cases (40.0%) of clinicallyAcute comorbidities
Disseminated intravascular coagulation 44 (8.6%) important bleeding occurred among patients with lower
Gastrointestinal bleeding 33 (6.4%) AGIH.
Hepatic failure 141 (27.4%)
In one case, surgical intervention was needed to stopHeart failure 141 (27.4%)
Hypotension 139 (27.0%) AGIH (total gastrectomy in AGIH due to gastric can-
Neurologic failure 85 (16.5%) cer). Patients with clinically important bleeding required
Oliguria 318 (61.9%)
a median of six (range 3 to 29) packed red cell units.Respiratory failure 251 (48.8%)
Sepsis 111 (21.6%) Clinical and endoscopic diagnoses of AGIH are re-
Systemic inflammatory response syndrome 286 (55.8%) ported in Tables 4 and 5. In most patients, upper AGIH
Chronic comorbidities diagnosis was made by the presence of bloody material in
Active malignancy 75 (24%) the nasogastric aspirate (24 cases) or melena (24 cases),Atherosclerotic vascular disease 177 (34.4%)
whereas hematemesis was observed less frequently. AnNoncirrhotic chronic hepatic disease 65 (12.7%)
Chronic renal insufficiency 145 (28.2%) endoscopic procedure was performed in 38 cases of up-
Liver cirrhosis 36 (7.0%) per AGIH and in all cases of lower AGIH: Among theChronic obstructive pulmonary disease 142 (27.6%)
cases of upper AGIH, 71% of patients (27 out of 38)Diabetes mellitus 105 (20.4%)
Immunodepression 72 (14%) had either erosions or ulcers in the esophagus or gastro-
Severe malnutrition (Class C of the Subjective duodenal tract.Global Assessment of Nutritional Status) 170 (33.1%)
Univariate associations between baseline variables
(that is, recorded at the time of admission) and AGIH
are reported in Table 6; statistically independent baseline
predictors of AGIH are shown in Table 7. The incidencepatients are shown in Table 2, and acute and chronic
of AGIH increased with severity of illness. It was highercomorbidities are shown in Table 3. AGIH episodes
in patients with chronic liver disease, in those with a lowwere observed in 69 out of 514 patients, with a cumulative
platelet count (,50,000 mm3), in the most severe casesincidence of 13.4% (95% CI, 10.6 to 16.7). The median
of ARF, and in de novo ARF (that is, in patients withouttime from referral to the unit to the first bleeding episode
pre-existing chronic renal failure). The same predictorswas six days (range 1 to 11). Upper AGIH occurred in
were identified when clinically important bleeding was59 out of 514 patients (11.5%), lower AGIH occurred
considered as the outcome, with the exception of noncir-in 10 out of 514 (1.9%); 40 out of 514 (7.8%) patients
rhotic hepatic disease and APACHE II score, whichhad clinically important bleeding. Thirty-six of the 59
cases (61%) of upper AGIH were clinically important were of borderline statistical significance (Fig. 1).
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Table 6. Univariate association between baseline variables and AGIH in ARF patients
Odds ratios 95% CI P value
Demographic data and provenance
Age .65 years 0.82 0.48–1.40 0.48
Male gender 0.85 0.50–1.42 0.53
APACHE II scorea 1.64 1.22–2.20 0.001
Transferred from other intensive care units 0.34 0.14–0.82 0.016
Medical vs. surgical patient 1.12 0.63–1.97 0.70
Transferred from emergency surgery 1.22 0.59–2.53 0.60
Acute comorbidities
Disseminated intravascular coagulation 1.75 0.80–3.82 0.18
Heart failure 1.29 0.75–2.23 0.37
Hepatic failure 2.17 1.28–3.66 0.005
Hypotension 1.95 1.15–3.30 0.016
Neurologic failure 1.69 0.91–3.14 0.10
Oliguria 2.07 1.16–3.70 0.010
Respiratory failure 1.18 0.71–1.96 0.53
Sepsis 1.23 0.68–2.23 0.50
Systemic inflammatory response syndrome 2.15 1.24–3.73 0.005
Chronic comorbidities
Active malignancy 2.13 1.24–3.67 0.008
Atherosclerotic vascular disease 0.80 0.47–1.39 0.43
Non-cirrhotic chronic hepatic disease 1.78 0.91–3.49 0.10
Chronic renal insufficiency 0.34 0.16–0.70 0.001
Liver cirrhosis 3.66 1.74–7.75 0.001
Chronic obstructive pulmonary disease 0.91 0.51–1.62 0.74
Diabetes mellitus 0.55 0.26–1.15 0.09
Immunodepression 1.88 0.99–3.55 0.06
Severe malnutrition (Class C of the Subjective
Global Assessment of Nutritional Status) 2.19 1.31–3.66 0.003
Coagulopathy
Low platelet count ,50,000 mm3 4.44 2.12–9.31 ,0.001
Low prothrombin activity ,35% 1.70 0.78–3.72 0.20
Renal function
Upper quartile serum creatinine level .7 mg/dL 1.33 0.77–2.31 0.31
Upper quartile BUN level .113 mg/dL 1.66 0.97–2.83 0.07
a For every ten point increase
Table 7. Independent predictors of AGIH as a complication in ARF
Beta Odds ratios
Coefficient (95% CI) P value
Low platelet count ,50000/mm3 1.3119 3.71 (1.70–8.11) 0.002
Liver cirrhosis 1.2169 3.38 (1.50–7.60) 0.005
De novo ARFb 1.0182 2.77 (1.30–5.90) 0.004
Non-cirhotic chronic hepatic disease 0.7994 2.22 (1.09–4.55) 0.036
Oliguria and high creatinine levels .7 mg/dL 0.7252 2.07 (1.10–3.88) 0.029
APACHE II scorea 0.0374 1.45 (1.05–2.01) 0.025
Constant 24.1298 — —
a For a 10 points increase in APACHE II score
b Coded 1 if chronic renal failure absent and 0 if otherwise
The prevalence of antihemostatic drug use during hos- patients with AGIH; when renal replacement treatment
was done, there was a relatively higher use of continuouspital stay is reported in Table 8. The use of both oral
anticoagulants and aspirin was significantly lower in sub- venovenous hemofiltration.
In-hospital mortality of the entire ARF cohort wasjects with AGIH. This likely reflects less frequent utiliza-
tion of such drugs in patients judged at risk of hemor- 39.1%: Mortality was 152 out of 445 (34.2%) in patients
who did not develop AGIH and 44 out of 69 (63.8%)rhage. In contrast, no major differences were found in
the use of low molecular weight heparin for deep venous in those with AGIH. No death from uncontrolled AGIH
occurred. Table 9 reports mortality according to the dif-thrombosis prophylaxis or heparin for hemodialysis. Re-
nal replacement therapy was performed more often in ferent types of AGIH. The crude odds ratio of death
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Fig. 1. Odd ratios and 95% CI from the
model of predictors of acute gastrointestinal
hemorrhage (AGIH; s) and from the model
of predictors of AGIH with clinically impor-
tant bleeding (h). APACHE is the acute phys-
iology and chronic health evaluation score,
version II.
Table 8. Antihemostatic drug use and procedures during stay in the nephrology unit
AGIH No AGIH P value
Oral anticoagulants 1/69 (1.5%) 38/445 (8.5%) 0.07
Aspirina 1/69 (1.5%) 57/445 (12.8%) 0.024
LMWHb 22/69 (31.9%) 170/445 (38.2%) 0.31
Renal replacement therapy 52/69 (75.4%) 268/445 (60.2%) 0.013
Continuous venovenous hemofiltration 14/52 (26.9%) 36/268 (13.4%) 0.009
Heparin during hemodialysis
(at least one session) 25/38 (65.8%) 129/222 (58.1%) 0.38
Artificial nutrition 62/69 (89.9%) 252/445 (56.6%) ,0.001
Enteral nutritionb 58/62 (93.6%) 235/252 (93.3%) 0.93
LMWH is low-molecular-weight heparins.
a At the time of admission and/or at any time during stay in the nephrology unit
b Enteral or enteral 1 parenteral nutrition in patients on artificial nutrition
Table 9. Mortality, APACHE II score and length of stay in ARF patients stratified according to different AGIH categories
Length of stay, daysa APACHE IIb
Mortality APACHE II (survivors) (survivors)
No AGIH 152/445 (34.2%) 22.8 (8.0) 23 (3–118) 20.1 (6.5)
AGIH (all cases) 44/69 (63.8%) 26.3 (8.5) 41 (8–128) 22.5 (6.6)
AGIH (clinically important bleeding) 27/40 (67.5%) 26.6 (8.1) 67 (14–128) 24.0 (7.9)
a Length of stay, reported as median (range)
b APACHE II score values reported as mean (SD)
associated with AGIH was 3.44 (95% CI, 2.03 to 5.83, were considered, length of stay was higher in patients with
AGIH (median 41; range 8 to 128) than in the other ARFP , 0.001). After adjusting for all baseline confounders,
incident AGIH was still a significant predictor of death patients (23; 3 to 118; Table 9). The relative increase in
mean length of stay in patients with AGIH was 54% (95%[odds ratio 2.57 (95% CI, 1.30 to 5.09), P 5 0.006;
Table 10]; odds ratios (and 95% CIs) associated with CI, 13 to 108%, P 5 0.006); after adjusting for all baseline
confounders, the length of stay remained 37% higher (1clinically important bleeding are also reported.
Median length of hospital stay was 20 days (range 1 to 87%, P 5 0.047). Table 10 shows the crude and adjusted
relative increase in mean length of stay associated withto 128) in the entire cohort and was 24 (3 to 128) in
patients who survived. When only surviving patients AGIH and with clinically important bleeding.
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Table 10. Crude and adjusted odd ratios of death and relative increase in length of hospital stay associated with all cases of
AGIH and AGIH with clinically important bleeding
AGIH
Clinically important
All cases bleeding
(N569) (N540)
Odds ratios of death (95% CI)a
3.44 3.79
Crude (2.03 to 5.83) (1.91 to 755)
2.57 2.57
Adjusted (1.30 to 5.10) (1.09 to 6.06)
% Increase in length of hospital stay (95% CI)
154% 1110%
Crude (113 to 1109%) (138 to 1218%)
137% 173%
Adjusted (11 to 187%) (113 to 1168%)
a 95% CI is 95% confidence interval
DISCUSSION AGIH and clinically important bleeding, and a clear
distinction between AGIH as complication or comorbid-The present study shows that AGIH is still a frequent
ity was made. Moreover, limiting the focus on AGIH ascomplication of ARF, and that in most cases is due to
a complication assured that the time of recording oferosions or ulcers in the upper gastrointestinal tract. The
the candidate predictors preceded bleeding on the timeseverity of underlying illness, ARF severity, low platelet
scale. Finally, stress ulcer syndrome pharmacologicalcount, and pre-existing liver disease represent significant
prophylaxis with H2-receptor antagonists was utilized inrisk factors. Once developed, AGIH in ARF patients
all patients.must be considered a risk indicator of death and in-
Acute gastrointestinal hemorrhage frequency in ARFcreased health resource utilization.
populations on systematic pharmacological prophylaxisAcute gastrointestinal hemorrhage and clinically im-
with H2-receptor antagonists has not been previouslyportant bleeding occurred in 13.4 and 8.2% of ARF
documented. Stress ulcer prophylaxis is now a commonpatients, respectively. With few exceptions, these values
practice at least in the intensive care units [33, 36–39],are lower than those reported in the literature [2–15].
and a recent meta-analysis on critically ill patients hasThe discrepancy might be due in part to the improve-
shown that prophylaxis with H2-receptor antagonists de-ments in general care of ARF patients that have occurred
creases the risk of gastrointestinal bleeding by approxi-in the last years and in part to some aspects of the man-
mately 50% [39]. However, as the cost of prophylaxis inagement of our ARF cohort, such as differences in tim-
low-risk patients is considered high [40], some authorsing, dose, or modality of renal replacement therapy or
have suggested that this intervention should be tailoredin the use of the heparin-free method for hemodialysis
only to high-risk subjects [41–43]. Our ARF patientsin patients judged to be at high hemorrhagic risk. Some
were free of other known major risk factors for AGIHlimitations of past studies should also be considered: the
(such as mechanical ventilation, burns, or central nervousselection of small and specific subgroups of ARF patients
system trauma), yet the incidence remained higher than[5, 8, 10, 12], the retrospective collection of data [2–7,
that observed in other populations at risk [33, 38]. Re-9–15], and the failure to differentiate clinically important
cently, Cook et al reported that in a subset of theirbleeding from the milder form of AGIH [2–15]. Finally,
critically ill patients on mechanical ventilation [44], amost of the previous studies were done before the era
high level of creatinine was the most important risk fac-of extensive use of pharmacological prophylaxis of upper
tor for gastrointestinal bleeding, whereas a previousgastrointestinal stress lesions.
study on their entire intensive care unit population failedOur study overcomes most of these problems. The
to demonstrate renal failure as an independent predictorARF population was fairly large (to our knowledge,
of AGIH [33]. Two studies on renal transplant patientslarger than any published so far). The pattern of referral
[45, 46] found a high incidence of bleeding—3 out of 24assured that more than 90% of incident ARF cases in
(12.5%) and 6 out of 33 (18.2%), respectively—which isthe hospital were referred to our unit [19]. The distribu-
similar to that found in our study. Renal transplant pa-tion of causes was well represented in our series [17, 19].
tients have multiple potential risk factors for bleeding,Data were prospectively collected without knowledge of
such as surgery and the use of steroids, which concurthe future outcome of the patient; uniform and widely
accepted criteria were employed for the diagnosis of with renal failure in explaining their greater propensity
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to develop AGIH. Our study shows that along with the Some limitations of the present study must be ac-
global severity of underlying illness (APACHE II score) knowledged.
and well-known prohemorrhagic conditions such as low First, the design of this study did not allow us to evalu-
platelet count and pre-existing liver disease, the severity ate the effect of different artificial nutrition techniques
of acute uremia was also an independent predictor of on the occurrence of AGIH. Moreover, no conclusion
AGIH. It is likely that the predictive value of the severity can be drawn about the effects of renal replacement
of uremia can be related to the hemorrhagic diathesis therapy modalities or dose on patient outcome. It is to
peculiar to the syndrome, which is characterized by al- be underscored that increasing the dose of renal replace-
tered platelet aggregability and platelet–vessel wall inter- ment therapy is associated with a better outcome in ARF
action [16]. Many factors are likely to be involved in patients [51]. In our study population, continuous hemo-
patients with acute or chronic uremia, such as increased filtration was more frequently utilized with respect to
synthesis of nitric oxide with secondarily reduced platelet hemodialysis in the patients with AGIH, but this finding
aggregation, interference of uremic toxins on GPIIb/IIa might simply reflect the prejudice of using continuous
platelet receptor binding to fibrinogen and von Wille- renal replacement therapies more often in sicker and
brand factor, anemia with negative rheologic effects on more hemodynamically unstable ARF patients, who also
platelet distribution across the vessel lumen [16]. are at higher risk for bleeding complications.
An endoscopic examination was performed in more We did not define the role of medications as risk fac-
than two thirds of the cases in our study, and this diagnos- tors for AGIH. In the present study, data regarding the
tic procedure provided detailed information on the use of medications relevant to hemostasis are in fact to
AGIH source in ARF. It is well known that the so-called be referred at the time of admission or at any time after
stress-related upper gastrointestinal tract lesions account admission; thus, we could not investigate either their
for the vast majority of lesions responsible for AGIH in role as prognostic variables at admission, or the temporal
the critically ill patient [47]. Our data confirm that even relationship between the administration of these drugs
in ARF patients, gastric ulcers and/or erosions are the and the occurrence of AGIH.
most common source of AGIH. Stress-related mucosal Finally, the ARF population considered in the present
injury in the critically ill is thought to originate from a study did not include subjects on mechanical ventilation,
complex interplay of aggressive luminal factors (normal a well-known risk factor for AGIH in critically ill patients
or increased acid secretion) and altered gastric mucosa [33]; therefore, we cannot exclude that the frequency of
defense mechanisms (reduced mucosal blood flow, muco- occurrence of AGIH could have been even higher if
sal barrier disruption, decreased mucus, and prostaglandin ARF patients on mechanical ventilation were included.
production, etc.) [47]. Duodenal ulcers accounted for a In conclusion, our study provides evidence that AGIH
substantial number of the lesions responsible of upper is still a frequent complication of ARF and is related to
AGIH. This is not surprising as the median time for both renal and extrarenal factors. AGIH in this clinical
AGIH after referral was six days; it is well known that condition carries a poor prognosis and increases length
in critically ill patients, late bleeding is usually due to of hospital stay. Thus, every effort should be made to
deeper and more distal lesions as compared with classic obtain more effective prevention than that provided by
stress ulcers [38, 48]. H2-receptor antagonists. This is a goal to be pursued by
Evidence regarding the role of AGIH as a prognostic future research.
factor in patients with ARF is controversial. Some older
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APPENDIXAGIH had a strikingly negative prognostic impact on
outcome, even after controlling for the different distribu- Acute comorbidities
tion of comorbidities; finally, length of hospital stay was Disseminated intravascular coagulation. Platelet count ,100 3
109/L and prothrombin time .16 seconds with a positive test for fibrinsignificantly increased in ARF patients with AGIH.
Fiaccadori et al: Gastrointestinal hemorrhage in ARF1518
split products or 2 U of fresh frozen plasma infused in the past 24 7. Kennedy AC, Burton JA, Luke R: Factors affecting the prognosis
in acute renal failure. Q J Med 165:73–86, 1973hours.
8. Anderson RJ, Linas SL, Berns AS, et al: Non oliguric acute renalGastrointestinal bleeding. Hematemesis or melena with or without
failure. N Engl J Med 19:1134–1138, 1977need for blood transfusion.
9. McMurray SD, Luft FC, Maxwell DR, et al: Prevailing patternHeart failure. Class IV New York Heart Association or low cardiac
and predictor variables in patients with acute tubular necrosis.output (cardiac index ,2.5 L/min per m2 or left ventricular ejection
Arch Intern Med 138:950–955, 1978fraction ,30%) or requiring inotropic support (dopamine .4 mg/kg
10. Lien J, Chan V: Risk factors influencing survival in acute renalper min and/or dobutamine whatever dose).
failure treated by hemodialysis. Arch Intern Med 145:2067–2069,Hepatic failure. Total bilirubin .4.0 mg/dL with prothrombin time
1985.16 seconds or alanine-aminotransferase .100 U/L or hepatic enceph-
11. Gornick CC, Kyellstrand CM: Acute renal failure complicatingalopathy.
aortic aneurysm surgery. Nephron 35:145–157, 1983Hypotension. Systolic BP 90 mm Hg for 2 hours in the 24 hours
12. Berisa F, Beaman M, Adu D, et al: Prognostic factors in acuteafter admission.
renal failure following aortic aneurysm surgery. Q J Med 76:689–Neurologic failure. Coma or deep stupor (Glasgow scale 6 without
698, 1990sedation).
13. Spiegel DM, Ullian ME, Zerbe GO, et al: Determinants of sur-Oliguria. Urinary output ,500 mL/24 hours or ,20 mL/hour in
vival and recovery in acute renal failure patients dialyzed in inten-the past 8 hours.
sive-care units. Am J Nephrol 11:44–47, 1991Respiratory failure. Arterial oxygen saturation ,90% or PaO2 ,60 14. Frost L, Pedersen RS, Bentzen S, et al: Short and long termmm Hg and/or PaCO2 .50 mm Hg. outcome in a consecutive series of 419 patients with acute dialysis-Sepsis. The systemic response to infection, manifested by two or
requiring renal failure. Scand J Urol Nephrol 27:453–462, 1993more of the following conditions as a result of infection: temperature
15. Klouche K, Cristol JP, Kaaki M, et al: Prognosis of acute renal
.388, heart rate .90 beats/min, respiratory rate .20 breaths/min or
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.10% immature (band) forms. physiology and management. Am J Med 96:168–174, 1994
Systemic inflammatory response syndrome (SIRS). The systemic in- 17. Fiaccadori E, Lombardi M, Leonardi S, et al: Prevalence and
flammatory response to a variety of severe clinical insults. The response clinical outcome associated with preexisting malnutrition in acute
is manifested by two or more of the following conditions: temperature renal failure: A prospective, cohort study. J Am Soc Nephrol 10:
.388, heart rate .90 beats/min, respiratory rate .20 breaths/min, or 581–593, 1999
PaCO2 ,32 mm Hg, WBC .12,000 cells/mm3 or ,4000 cells/mm3, or 18. Fiaccadori E, Gonzi GL, Zambrelli P, et al: Cardiac arrhythmias
.10% immature (band) forms. during central venous catheter procedures in acute renal failure:
A prospective study. J Am Soc Nephrol 7:1079–1084, 1996
Chronic comorbidities 19. Fiaccadori E, Maggiore U, Lombardi M, et al: Predicting patient
outcome from acute renal failure comparing three general severityActive malignancy. Nonskin cancer.
of illness scoring systems. Kidney Int 58:283–292, 2000Atherosclerotic vascular disease. Angina or myocardial infarction
20. Bullock M, Umel A, Finkelstein M, et al: The assessment ofor claudication or history of vascular bypass surgery.
risk factor in 462 patients with acute renal failure. Am J KidneyChronic noncirrhotic hepatic disease. History of liver disease (heavy
Dis 5:97–103, 1985alcohol use, virus B or C hepatitis, etc.) without liver cirrhosis diagnosis
21. Rasmussen H, Pitt E, Ibels L, et al: Prediction of outcome in(see definition of liver cirrhosis).
acute renal failure by discriminant analysis of clinical variables.Chronic renal insufficiency. Serum creatinine .3.0 mg/dL before
Arch Intern Med 145:2015–2018, 1985the ARF episode.
22. Corwin H, Teplick R, Schreiber M, et al: Prediction of outcomeChronic obstructive pulmonary disease (COPD). History, physical
in acute renal failure. Am J Nephrol 7:8–12, 1987exam, and X-rays, compatible with chronic obstructive pulmonary dis-
23. Lohr J, MacFarlane M, Grantham J: A clinical index to predictease, resulting in functional disability and/or requiring chronic bron-
survival in acute renal failure patients requiring dialysis. Amchodilator therapy and/or FEV1 ,75% predicted.
J Kidney Dis 11:254–259, 1988Diabetes mellitus. Treatment before hospitalization.
24. Turney J, Marshall D, Broownjohn A, et al: The evolution ofImmunodepression. Therapy that suppresses resistance to infection,
acute renal failure, 1956-1988. Q J Med 74:83–104, 1988for example, immunosuppression, chemotherapy, radiation, long-term
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